The Use of Ultrasound Detection of Lipohypertrophy to Improve Glycemic Control (NCT05377268)
The Use of Machine Learning Detection of Lipohypertrophy to Improve Glycemic Variability
🩺 Plain-English Summary (8th-Grade Level)
Lipohypertrophy is swelling of the fatty tissue located below the skin ("subcutaneous tissue") where many patients with diabetes inject their insulin. Lipohypertrophy can sometimes be felt as firm swelling, lumps or small bumps near insulin injection sites. Previous studies have shown that injecting insulin into areas of lipohypertrophy can affect how insulin is absorbed, and can increase insulin requirements in patients. New data suggest that lipohypertrophy can be detected using ultrasound technology. The ultrasonographic presence of changes to the subcutaneous tissue without swelling that can be felt ("subclinical lipohypertrophy") and the effect of injecting insulin into these sites is unknown. 100 people will participate in the Phase 1 of this study. In the second phase of the study, 40 patients identified with subclinical lipohypertrophy in Phase 1 will be asked to participate in the randomized study using crossover design by checking your glucose levels.
Who can join: Review the eligibility criteria below.
Location: Vancouver General Hospital Diabetes Centre — Vancouver, British Columbia
Age range: 19 Years to 80 Years
🧪 Interventions in This Study
- LH Protocol (PROCEDURE)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Vancouver General Hospital Diabetes Centre — Vancouver, British Columbia
📞 Contact the Study Coordinator
Phone: (604) 875-5115
Email: boris.feldman@vch.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diabetes Mellitus
- The REST Study for CGM Use in Older Adults With Insulin-treated Diabetes — Boston, Massachusetts
- Oral Anti Diabetic Agents in the Hospital — Atlanta, Georgia
- Full Plate Living Nutrition Education Program — Madison, Wisconsin
- Evaluation of Arts-Based Storytelling Program in Adolescents With Diabetes — San Francisco, California
- Impact of Per Oral Pyloromyotomy (POP) on Glycemic Control in Diabetes — Cleveland, Ohio
- Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years — Charlestown, Massachusetts
Explore by condition: All Diabetes Mellitus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.